

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss.

BOARD OF REGISTRATION  
IN PHARMACY

_____	)	
Board of Registration in Pharmacy,	)	
Petitioner	)	
	)	
v.	)	Docket Nos. PHA-2024-0147,
	)	PHA-2024-0148, PHA-2024-0168,
OPTION CARE,	)	PHA-2024-0170, PHA-2024-0171,
License Number: DS90107	)	PHA-2024-0233, PHA-2024-0234
Expiration Date: 12/31/2025	)	
Respondent	)	
_____	)	

**CONSENT AGREEMENT FOR REPRIMAND**

The Massachusetts Board of Registration in Pharmacy (Board) and Option Care (Pharmacy or Licensee), a pharmacy licensed by the Board, DS90107, do hereby stipulate and agree that the following information shall be entered into and become a permanent part of the Licensee’s record maintained by the Board:

1. The Licensee acknowledges the Board opened Complaints against its Massachusetts pharmacy license related to the conduct set forth in Paragraph 2, identified as Docket Numbers PHA-2024-0147, PHA-2024-0148, PHA-2024-0168, PHA-2024-0170, PHA-2024-0171, PHA-2024-0233, PHA-2024-0234 (Complaint).
2. The Licensee and the Board agree to resolve these Complaints without making any admissions or findings and without proceeding to a formal adjudicatory hearing. The Complaints allege the following:
  - a. On or about May 2, 2024, a report of “Defective Drug Preparation” was submitted by the Licensee to the Board of Registration in Pharmacy indicating a prescription for ertapenem 1gm intravenously was compounded and assigned an incorrect “discard after date”. [PHA-2024-0147]
  - b. On or about March 18, 2024, a report of “Defective Drug Preparation” was submitted by the Licensee to the Board of Registration in Pharmacy indicating a refill of a prescription for daptomycin 250 mg intravenously (IV) was compounded and mislabeled. [PHA-2024-0148]
  - c. On or about June 12, 2024, a report of “Defective Drug Preparation” was submitted by the Licensee to the Board of Registration in Pharmacy indicating a prescription

for ceftriaxone 2gm intravenously (IV) was compounded and mislabeled. [*PHA-2024-0168*]

- d. On or about June 10, 2024 a report of “Defective Drug Preparation” was submitted by the Licensee to the Board of Registration in Pharmacy indicating a refill of a prescription for custom parenteral nutrition was compounded without lipids. [*PHA-2024-0170*]
  - e. On or about June 18, 2024, a report of “Defective Drug Preparation” was submitted by the Licensee to the Board of Registration in Pharmacy indicating a prescription for parenteral nutrition was compounded with 96 mcg of selenium instead of the prescribed 60 mcg of selenium. [*PHA-2024-0171*]
  - f. On or about June 28, 2024, a report of “Defective Drug Preparation” was submitted by the Licensee to the Board of Registration in Pharmacy indicating a refill of a prescription for imipenem-cilastatin 750 mg (500 mg + 250 mg/18 bags) was dispensed as imipenem-cilastatin 500 mg (36 bags/18 doses). [*PHA-2024-0233*]
  - g. On or about July 8, 2024, a report of “Defective Drug Preparation” was submitted by the Licensee to the Board of Registration in Pharmacy indicating a refill of a prescription for amphotericin B liposomal 150 mg/Dextrose 5% in water (“D5W”) 400 ml was dispensed in Dextrose 5% in normal saline (“D5NS”). [*PHA-2024-0234*]
3. The Board and Licensee acknowledge and agree that based upon the information described in Paragraph 2 the Board could find the Licensee in violation of 247 CMR 10.03(1)(v) which may be grounds for discipline per 247 CMR 10.03(1)(a).
  4. The Licensee agrees that the Board shall impose a REPRIMAND on its license based on the facts described in Paragraph 2, effective as of the date on which the Board signs this Agreement (Effective Date).
  5. The Board agrees that in return for the Licensee’s execution and successful compliance with all the requirements of this Agreement, the Board will not prosecute the Complaint.
  6. The Licensee understands that it has a right to formal adjudicatory hearing concerning the Complaint and that during said adjudication the Licensee would possess the right to confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on its own behalf, to contest the allegations, to present oral argument, to appeal to the courts, and all other rights as set forth in the Massachusetts Administrative Procedures Act, G.L. c. 30A, and the Standard Adjudicatory Rules of Practice and Procedure, 801 CMR 1.01 *et seq.* The Pharmacy further understands that by executing this Agreement the Licensee is knowingly and voluntarily waiving its right to a formal adjudication of the Complaint.

7. The Licensee acknowledges that it has been at all times represented by Counsel or otherwise free to seek and use legal counsel in connection with the Complaint and this Agreement.
8. The Licensee acknowledges that after the Effective Date, the Agreement constitutes a public record of disciplinary action by the Board subject to the Commonwealth of Massachusetts' Public Records Law, G.L. c. 4, § 7. The Board may forward a copy of this Agreement to other licensing boards, law enforcement entities, and other individuals or entities as required or permitted by law.
9. The Licensee understands and agrees that entering into this Agreement is a voluntary and final act and not subject to reconsideration, appeal or judicial review.
10. The individual signing this Agreement certifies that they are authorized to enter into this Agreement on behalf of the Licensee, and that they have read this Agreement.

9/23/25  
Date

  
(signature)

Luke Whitworth  
(print name)

Michael J. Godek  
Michael Godek, R. Ph.  
Executive Director  
Board of Registration in Pharmacy

9/26/2025  
Effective Date of Reprimand Agreement

Fully Signed Agreement Sent to Licensee on Sept. 26, 2025 by Certified Mail  
No. 9589 0710 5270 0684 7010 30